bioRxivCancer Biology
Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2015 and 2019 at the Uganda Cancer Institute
Paul Katongole, Obondo J. Sande, Mulumba Yusuf, Moses Joloba, Steven J Reynolds, Nixon Niyonzima
Abstract
Background Prostate cancer is the second most common cancer among men in Uganda, with over 2086 incident cases in 2018. This study’s objective was to report the clinical characteristics and primary management of men diagnosed with prostate cancer at the Uganda Cancer Institute from 1st January 2015 to 31st December 2019.Methods Records from all men diagnosed with Prostate cancer at the Uganda Cancer Institute from 1st January 2015 to 31st December 2019 were reviewed. Clinical characteristics and primary treatment were recorded. Risk categorization was done using the European Society for Medical Oncology prostate cancer risk group classification.Results total of 874 medical records for men diagnosed with prostate cancer was retrieved. The median age was 70 years (interquartile range 64–77). In this study, 501 (57.32%) patients had localized disease. Among patients with localized disease, 2 (0.23%) were classified as low-risk, 5 (0.53%) as intermediate-risk, and 494 (56.52%) as high-risk. Three hundred seventy-three (373) patients had metastatic disease at diagnosis. Among patients with distant metastases, the most common site of metastases was bone 143 (16.36%), followed by spinal cord 54 (6.18%), abdomen 22 (2.52%), and lungs 14 (1.60%). Regarding the primary treatment options majority of the patients were on chemotherapy 384(43.94%) followed by hormonal therapy 336 (38.44%) and radiotherapy 127 (14.53%).Conclusion The majority of the patients diagnosed with prostate cancer at the Uganda Cancer Institute presented with advanced disease. The primary treatments were mostly chemotherapy, hormonal therapy, and radiotherapy. There is a need to improve prostate cancer screening in regional health care facilities and the communities to enhance early detection and management of prostate cancer.View Full Text
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular analysis of prostate cancer: prostate tissue and urine proteomics based approach
- Assessing Knowledge, Uptake and Factors associated with cervical cancer screening among women in selected communities of Wakiso District in Uganda: A population-based study
Robert Bulamba, Emmanuel Kyasanku, … Gertrude F. Nakigozi·PLoS ONEPeer-reviewed·Sep 3, 2025
- Low abundance of circulating tumor DNA in localized prostate cancer
S. Thomas Hennigan, Shana Y. Trostel, … Adam G. Sowalsky·JCO Precision OncologyPeer-reviewed·Sep 9, 2019
- Heterogeneity and genomic evolution of metastatic prostate cancer
Sijia Wu, Zhennan Lu, … Liyu Huang·bioRxiv·Sep 1, 2023
- Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian population
Emily Toscano, Valentina Maggio, … Rosanna Paciucci·Frontiers in OncologyPeer-reviewed·Aug 13, 2024
- Ancestry-Dependent Immunologic and Prognostic Effects Characterize the Prostate Cancer Urinary Proteome
Annie Ha, Jaron Arbet, … Thomas Kislinger·JNCI Journal of the National Cancer InstitutePeer-reviewed·Sep 11, 2026